Donafenib Combine With Sintilimab and HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）in the First-line Treatment of Unresectable Hepatocellular Carcinoma

Summary

The investigators design a phase IIB clinical study to explore the efficacy and safety of Donafenib combined with Sintilimab and HAIC in the first-line treatment of unresectable hepatocellular carcinoma

Timeline

Start

2021-12

Primary completion

2023-12

Completion

2024-12

Publications

• Gao W, Pan ZL, Zhao XH, Yang L, Cao JB, Li DY, Zheng HJ, Liu C, Li GT, Bao X, Liu XM, Zhang WH, Zhu XL, Xiao BH, Song TQ, Li Q, Lu W, Xing WG, Zhang W. Donafenib and sintilimab combined with hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma: a prospective, single-arm phase II trial (DoHAICs study). EClinicalMedicine. 2025 May 5;83:103217. doi: 10.1016/j.eclinm.2025.103217. eCollection 2025 May.

Drugs

Indications